Compare RDWR & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDWR | EVO |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | Israel | Germany |
| Employees | N/A | 4553 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 994.5M |
| IPO Year | 2000 | N/A |
| Metric | RDWR | EVO |
|---|---|---|
| Price | $29.90 | $2.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $32.50 | $7.00 |
| AVG Volume (30 Days) | ★ 209.4K | 29.9K |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.65 | $1.37 |
| Revenue Next Year | $8.62 | $10.05 |
| P/E Ratio | $59.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.68 | $2.31 |
| 52 Week High | $31.92 | $4.42 |
| Indicator | RDWR | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 60.62 | 51.49 |
| Support Level | $23.45 | $2.60 |
| Resistance Level | $31.92 | $3.82 |
| Average True Range (ATR) | 1.28 | 0.07 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 97.86 | 88.89 |
Radware Ltd is a provider of application security and delivery solutions for multi-cloud environments. Its solutions secure the digital experience by providing infrastructure, application, and network protection and availability services to companies globally. Its solutions are deployed by, among others, enterprises, carriers, and cloud service providers. The company offers solutions in two main categories: Products offers a range of cloud-based security-as-a-service subscriptions, on-premises hardware and software products, and product subscriptions (or a combination of these) to customers; and Services offers managed services, professional services, technical support and training and certification to customers and partners.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.